Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Drug Category: Array
Conference Category: Array
Lead Author: Lunning M, et al.
Published Date: 20/06/2015
Download Link: /wp-content/uploads/2019/03/1303%20Lugano%202015%20FINAL.PDF
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top